Global patterns of non-Hodgkin lymphoma in 2020

Allini Mafra*, Mathieu Laversanne, Mary Gospodarowicz, Paulo Klinger, Neimar De Paula Silva, Marion Piñeros, Eva Steliarova-Foucher, Freddie Bray, Ariana Znaor

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

17 Citations (Scopus)


We evaluated the global patterns of non-Hodgkin lymphoma (NHL) in 2020 using the estimates of NHL incidence and mortality in 185 countries that are part of the GLOBOCAN 2020 database, developed by the International Agency for Research on Cancer (IARC). As well as new cases and deaths of NHL, corresponding age-standardized (world) rates (ASR) of incidence and mortality per 100 000 person-years were derived by country and world region. In 2020, an estimated 544 000 new cases of NHL were diagnosed worldwide, and approximately 260 000 people died from the disease. Eastern Asia accounted for a quarter (24.9%) of all cases, followed by Northern America (15.1%) and South-Central Asia (9.7%). Incidence rates were higher in men than in women, with similar geographical patterns. While the incidence rates were highest in Australia and New Zealand, Northern America, Northern Europe and Western Europe (>10/100 000 for both sexes combined), the highest mortality rates (>3/100 000) were found in regions in Africa, Western Asia and Oceania. The large variations and the disproportionately higher mortality in low- and middle-income countries can be related to the underlying prevalence and distribution of risk factors, and to the level of access to diagnostic and treatment facilities.

Original languageEnglish
Pages (from-to)1474-1481
Number of pages8
JournalInternational Journal of Cancer
Issue number9
Publication statusPublished - 1 Nov 2022
Externally publishedYes


  • Africa/epidemiology
  • Europe/epidemiology
  • Female
  • Global Health
  • Humans
  • Incidence
  • Lymphoma, Non-Hodgkin/epidemiology
  • Male
  • North America/epidemiology


Dive into the research topics of 'Global patterns of non-Hodgkin lymphoma in 2020'. Together they form a unique fingerprint.

Cite this